Masatinib
| Code | Size | Price |
|---|
| SYN-1053-M100 | 100 mg | Enquire |
Quantity:
| SYN-1053-M001 | 1 mg | £63.00 |
Quantity:
| SYN-1053-M005 | 5 mg | £80.00 |
Quantity:
| SYN-1053-M010 | 10 mg | £115.00 |
Quantity:
| SYN-1053-M050 | 50 mg | £420.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
AB1010; Masivet
Appearance:
Solid.
CAS:
790299-79-5
EClass:
32160000
Form (Short):
liquid
InChi:
InChI=1S/C28H30N6OS/c1-20-5-10-24(16-25(20)31-28-32-26(19-36-28)23-4-3-11-29-17-23)30-27(35)22-8-6-21(7-9-22)18-34-14-12-33(2)13-15-34/h3-11,16-17,19H,12-15,18H2,1-2H3,(H,30,35)(H,31,32)
InChiKey:
WJEOLQLKVOPQFV-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 790299-79-5. Formula: C28H30N6OS. MW: 498.7. Masitinib is a potent, orally available protein tyrosine kinase inhibitor targeting c-Kit, PDGFR and FGFR3. It demonstrates activity for Kit and PDGFRalpha/beta with IC(50) values of 200nM, 540nM and 800nM respectively. It shows weak inhibition of ABL and c-Fms.
Molecular Formula:
C28H30N6OS
Molecular Weight:
498.7
Package Type:
Plastic Vial
Product Description:
Masitinib is a potent, orally available protein tyrosine kinase inhibitor targeting c-Kit, PDGFR and FGFR3. It demonstrates activity for Kit and PDGFRalpha/beta with IC(50) values of 200nM, 540nM and 800nM respectively. It shows weak inhibition of ABL and c-Fms.
Purity:
>95%
Solubility Chemicals:
Soluble in DMSO or ethanol.
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT: P. Dubreuil, et al.; PLoS One 4, e7258 (2009)
Related Products
| Product Name | Product Code | Supplier | Genistein | AG-CN2-0427 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|